UY28915A1 - Derivados de tetraazabenzo (e)azuleno y sus análogos - Google Patents

Derivados de tetraazabenzo (e)azuleno y sus análogos

Info

Publication number
UY28915A1
UY28915A1 UY28915A UY28915A UY28915A1 UY 28915 A1 UY28915 A1 UY 28915A1 UY 28915 A UY28915 A UY 28915A UY 28915 A UY28915 A UY 28915A UY 28915 A1 UY28915 A1 UY 28915A1
Authority
UY
Uruguay
Prior art keywords
azuleno
tetraazabenzo
analogs
derivatives
compounds
Prior art date
Application number
UY28915A
Other languages
English (en)
Inventor
Marlys Hammond
Kimberly O Keefe Cameron
Richard Louis Elliott
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY28915A1 publication Critical patent/UY28915A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta invención se refiere a agonistas CCK-A de fórmula en que R1-R4, A,B,X,D,E y G son como se definen en la memoria descriptiva, así como, entre otras cosas, las composiciones farmacéuticas que contienen los compuestos y los métodos para usar los compuestos y composiciones. Los compuestos son útiles para tratar la obesidad.
UY28915A 2004-05-25 2005-05-23 Derivados de tetraazabenzo (e)azuleno y sus análogos UY28915A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57403304P 2004-05-25 2004-05-25

Publications (1)

Publication Number Publication Date
UY28915A1 true UY28915A1 (es) 2005-12-30

Family

ID=34967684

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28915A UY28915A1 (es) 2004-05-25 2005-05-23 Derivados de tetraazabenzo (e)azuleno y sus análogos

Country Status (26)

Country Link
US (2) US7265104B2 (es)
EP (1) EP1753766A1 (es)
JP (1) JP4069159B2 (es)
CN (1) CN1950374A (es)
AP (1) AP2006003768A0 (es)
AR (1) AR049187A1 (es)
AU (1) AU2005247693A1 (es)
BR (1) BRPI0510273A (es)
CA (1) CA2568056A1 (es)
CR (1) CR8753A (es)
EA (1) EA010888B1 (es)
EC (1) ECSP067025A (es)
GE (1) GEP20094723B (es)
GT (1) GT200500119A (es)
IL (1) IL178220A0 (es)
MA (1) MA28605B1 (es)
NL (1) NL1029105C2 (es)
NO (1) NO20064288L (es)
PA (1) PA8634101A1 (es)
PE (1) PE20060363A1 (es)
SV (1) SV2006002127A (es)
TN (1) TNSN06386A1 (es)
TW (1) TWI297688B (es)
UA (1) UA84208C2 (es)
UY (1) UY28915A1 (es)
WO (1) WO2005116034A1 (es)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177438A1 (en) * 2005-02-08 2006-08-10 New England Medical Center Methods of altering absorption of hydrophobic compounds
EP1937297A2 (en) * 2005-09-08 2008-07-02 Gastrotech Pharma A/S Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
AU2007320906A1 (en) 2006-11-13 2008-05-22 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
JP5313161B2 (ja) * 2006-12-11 2013-10-09 メルク・シャープ・アンド・ドーム・コーポレーション ボンベシンレセプターサブタイプ−３調節因子としての置換ジアゼピンスルホンアミド
AU2008219723A1 (en) * 2007-02-28 2008-09-04 Merck Sharp & Dohme Corp. Substituted benzodiazepinones, benzoxazepinones and benzothiazepinones as sodium channel blockers
ES2748136T3 (es) 2007-10-15 2020-03-13 United Animal Health Inc Método para aumentar el rendimiento de las crías
US20100317642A1 (en) * 2007-10-15 2010-12-16 Inventis Dds Pvt Limited Pharmaceutical composition of orlistat
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
MX2011004575A (es) * 2008-11-13 2011-06-01 Hoffmann La Roche Espiro-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo [e] azulenos.
JP5384659B2 (ja) * 2008-11-18 2014-01-08 エフ．ホフマン−ラ ロシュ アーゲー ジヒドロテトラアザベンゾアズレンのアルキルシクロヘキシルエーテル
MY150837A (en) * 2008-11-28 2014-02-28 Hoffmann La Roche Arylcyclohexylethers of dihydrotetraazabenzoazulenes for use as vasopressin via receptor antagonists
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
JP2012515760A (ja) 2009-01-20 2012-07-12 ファイザー・インク 置換ピラジノンアミド
WO2010086820A1 (en) 2009-02-02 2010-08-05 Pfizer Inc. 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof
TW201040174A (en) 2009-02-03 2010-11-16 Pfizer 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one derivatives
TW201040175A (en) 2009-02-04 2010-11-16 Pfizer 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one derivatives
PL2406253T3 (pl) 2009-03-11 2013-10-31 Pfizer Pochodne benzofuranylu jako inhibitory glukokinazy
EP2406230A1 (en) 2009-03-11 2012-01-18 Pfizer Inc. Substituted indazole amides and their use as glucokinase activators
US20120095028A1 (en) 2009-03-20 2012-04-19 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
PE20120399A1 (es) 2009-06-05 2012-04-24 Pfizer Derivados del l-(piperidin-4-il)-pirazol como moduladores de gpr 119
CN102482312A (zh) 2009-08-26 2012-05-30 赛诺菲 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
EP2480551A1 (en) 2009-09-23 2012-08-01 Pfizer Inc. Gpr 119 modulators
CA2777857C (en) 2009-11-02 2014-12-02 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
JP2013510191A (ja) 2009-11-10 2013-03-21 ファイザー・インク Ｎ−２ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害薬
PL2499139T3 (pl) 2009-11-10 2014-04-30 Pfizer N1-pirazolospiroketonowe inhibitory karboksylazy acetylo-CoA
US20120295845A1 (en) 2009-11-23 2012-11-22 Pfizer Inc Imidazo-pyrazoles as gpr119 inhibitors
US20110160143A1 (en) * 2009-12-28 2011-06-30 Perricone Nicholas V Topical Acyl Glutathione Psoriasis Compositions
RS54383B1 (en) 2010-03-19 2016-04-28 Pfizer Inc. 2,3-DIHYDRO-1H-INDEN-1-IL-2,7-DIAZASPIRO DERIVATIVES [3.6] NONANES AND THEIR USE AS ANTAGONISTS OR INVERNING AGELISTS OF GRELIN RECEPTORS
US8420633B2 (en) 2010-03-31 2013-04-16 Hoffmann-La Roche Inc. Aryl-cyclohexyl-tetraazabenzo[e]azulenes
WO2011123678A2 (en) 2010-03-31 2011-10-06 Arqule, Inc. Substituted benzo-pyrido-triazolo-diazepine compounds
US8461151B2 (en) 2010-04-13 2013-06-11 Hoffmann-La Roche Inc. Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes
US8492376B2 (en) 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8481528B2 (en) 2010-04-26 2013-07-09 Hoffmann-La Roche Inc. Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8513238B2 (en) 2010-05-10 2013-08-20 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes
WO2011158149A1 (en) 2010-06-18 2011-12-22 Pfizer Inc. 2-(3,5-disubstitutedphenyl)pyrimidin-4(3h)-one derivatives
EP2621493B1 (en) 2010-09-30 2016-08-17 Pfizer Inc N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
MX2013004733A (es) 2010-10-29 2013-07-02 Pfizer Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
AU2011346670B2 (en) 2010-12-23 2015-05-07 Pfizer Inc. Glucagon receptor modulators
CN104744370A (zh) 2011-02-08 2015-07-01 辉瑞大药厂 胰高血糖素受体调节剂
AU2012221704B2 (en) 2011-02-23 2013-12-05 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
SG194142A1 (en) 2011-04-22 2013-11-29 Pfizer Pyrazolospiroketone derivatives for use as acetyl - coa carboxylase inhibitors
CA2841757A1 (en) 2011-07-15 2013-01-24 Etzer Darout Gpr 119 modulators
CN103732578B (zh) 2011-07-22 2015-08-12 辉瑞大药厂 喹啉基胰高血糖素受体调节剂
JP6043355B2 (ja) 2011-08-31 2016-12-14 ファイザー・インク ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP2015515472A (ja) 2012-04-06 2015-05-28 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害薬
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2872154C (en) 2012-05-04 2016-08-23 Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds as inhibitors of app, bace1 and bace2
BR112014032913A2 (pt) 2012-06-29 2017-06-27 Pfizer novas 4-(amino-substituídas)-7h-pirrolo[2,3-d]pirimidinas como inibidores de lrrk2
US9260455B2 (en) 2012-09-20 2016-02-16 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
JP2016502978A (ja) 2012-12-11 2016-02-01 ファイザー・インク ＢＡＣＥ１の阻害剤としてのヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
CA2893333C (en) 2012-12-19 2017-10-24 Pfizer Inc. Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
CA2897678A1 (en) 2013-02-13 2014-08-21 Pfizer Inc. Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EP3055300B1 (en) 2013-10-09 2018-03-07 Pfizer Inc Antagonists of prostaglandin ep3 receptor
CN103664675B (zh) * 2013-11-27 2016-05-18 浙江省诸暨合力化学对外贸易有限公司 一种2-氯-n-(4-氟苯基)-n-异丙基乙酰胺的制备方法
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
CN106103425A (zh) 2014-03-17 2016-11-09 辉瑞公司 用于治疗代谢及相关病症的二酰甘油酰基转移酶2抑制剂
JP6111002B1 (ja) 2014-04-10 2017-04-05 ファイザー・インク ２−アミノ−６−メチル−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル−１，３−チアゾール−４−イルアミド
WO2016092413A1 (en) 2014-12-10 2016-06-16 Pfizer Inc. Indole and indazole compounds that activate ampk
JP2017538769A (ja) 2014-12-22 2017-12-28 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
CN107787322B (zh) 2015-06-17 2023-07-07 辉瑞大药厂 三环化合物以及它们作为磷酸二酯酶抑制剂的用途
EP3350178B1 (en) 2015-09-14 2021-10-20 Pfizer Inc. Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors
JP2018531923A (ja) 2015-09-24 2018-11-01 ファイザー・インク Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド
WO2017051303A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
WO2017051294A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
RU2696269C1 (ru) 2015-12-29 2019-08-01 Пфайзер Инк. Замещенные 3-азабицикло[3.1.0]гексаны в качестве ингибиторов кетогексокиназы
CN105524069A (zh) * 2016-02-25 2016-04-27 江苏理工学院 一种新型胆囊收缩毒受体拮抗剂类似物及其合成方法
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
CN112955147A (zh) 2018-08-31 2021-06-11 辉瑞公司 用于治疗nash/nafld和相关疾病的组合
EP3972596A1 (en) 2019-05-20 2022-03-30 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
CN112573494B (zh) * 2020-12-23 2022-06-21 西南石油大学 一种利用水合物法的氦精制装置
WO2023026180A1 (en) 2021-08-26 2023-03-02 Pfizer Inc. Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
WO2024125602A1 (en) 2022-12-15 2024-06-20 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2318673A1 (de) * 1973-04-13 1974-11-07 Boehringer Sohn Ingelheim Neue substituierte triazolo-1,5benzodiazepine
IE41197B1 (en) * 1973-05-29 1979-11-07 Squibb & Sons Inc 4h-s-triazolo (4,3-a)(1,5)benzodiazepin-5-ones
US4080323A (en) * 1977-03-07 1978-03-21 Hoffmann-La Roche Inc. Imidazo [1,5-a][1,5] benzodiazepines
US4118386A (en) 1977-04-04 1978-10-03 Hoffmann-La Roche Inc. Synthesis of imidazo[1,5-a]diazepine-3-carboxylates
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
AU1537292A (en) 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
GB9307833D0 (en) * 1993-04-15 1993-06-02 Glaxo Inc Modulators of cholecystokinin and gastrin
FR2716195B1 (fr) 1994-02-14 1996-06-21 Sanofi Sa Dérivés de 3-acylamino-5-phényl-1,4-benzodiazépin-2-one polysubstitués, leur procédé de préparation et les compositions pharmaceutiques les contenant.
KR970702274A (ko) 1994-04-14 1997-05-13 앨런 헤스케쓰 콜레시스토키닌 또는 가스트린을 조절하는 5-헤테로시클릭-1, 5-벤조디아제핀(CCK or Gastrin Modulating 5-Heterocyclic-1,5-Benzodiazepines)
PE27497A1 (es) * 1994-04-15 1997-08-07 Glaxo Inc Derivados de 1,5 benzodiazepina
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
WO2000027845A1 (en) 1998-11-10 2000-05-18 Merck & Co., Inc. Spiro-indolines as y5 receptor antagonists
AR022044A1 (es) 1999-05-06 2002-09-04 Glaxo Group Ltd Derivados de 1,5-benzodiazepina
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
US6462053B1 (en) 1999-08-20 2002-10-08 Banyu Pharmaceutical Co., Ltd. Spiro compounds
US6566367B2 (en) 2000-12-12 2003-05-20 Pfizer Inc. Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines
US6924291B2 (en) 2001-01-23 2005-08-02 Merck & Co., Inc. Process for making spiro isobenzofuranone compounds
US6605720B1 (en) 2002-01-28 2003-08-12 Merck & Co., Inc. Process for making spirolactone compounds

Also Published As

Publication number Publication date
GEP20094723B (en) 2009-07-10
AP2006003768A0 (en) 2006-10-31
AU2005247693A1 (en) 2005-12-08
US7265104B2 (en) 2007-09-04
TWI297688B (en) 2008-06-11
JP4069159B2 (ja) 2008-04-02
GT200500119A (es) 2006-01-12
US7358242B2 (en) 2008-04-15
NL1029105A1 (nl) 2005-11-30
SV2006002127A (es) 2006-02-15
US20070265193A1 (en) 2007-11-15
PE20060363A1 (es) 2006-05-08
MA28605B1 (fr) 2007-05-02
UA84208C2 (en) 2008-09-25
JP2008500326A (ja) 2008-01-10
CR8753A (es) 2006-12-13
PA8634101A1 (es) 2006-06-02
WO2005116034A1 (en) 2005-12-08
TW200609235A (en) 2006-03-16
NL1029105C2 (nl) 2006-06-13
ECSP067025A (es) 2006-12-29
IL178220A0 (en) 2006-12-31
TNSN06386A1 (fr) 2008-02-22
EA200601773A1 (ru) 2007-06-29
CN1950374A (zh) 2007-04-18
BRPI0510273A (pt) 2007-10-30
AR049187A1 (es) 2006-07-05
CA2568056A1 (en) 2005-12-08
US20050267100A1 (en) 2005-12-01
NO20064288L (no) 2006-10-23
EA010888B1 (ru) 2008-12-30
EP1753766A1 (en) 2007-02-21

Similar Documents

Publication Publication Date Title
UY28915A1 (es) Derivados de tetraazabenzo (e)azuleno y sus análogos
ECSP088221A (es) Agonistas adrenoreceptores alfa2c
CU23464B7 (es) (1,8)naftidirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
GT200600117A (es) Nuevos compuestos farmaceuticos
CL2008002132A1 (es) Compuestos derivados de sulfonamidas, moduladores de trpm8; composiciones farmaceuticas que comprenden a dichos compuestos; y uso de dichos compuestos en el tratamiento del dolor neuropatico, dolor inflamatorio, ansiedad, depresion, hiperalgesia inflamatoria, entre otras.
UY30748A1 (es) Compuesto0s novedosos
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
ECSP088590A (es) Derivados de aminoácido multicíclicos y sus métodos de uso
ECSP109987A (es) Métodos y compuestos útiles para preparar inhibidores del co-transportador 2 sodio glucosa
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
DOP2009000133A (es) Derivados de indol como agonistas de los receptores s1p1
ECSP109844A (es) Espirociclos como inhibidores de la 11-beta hidroxiesteroide deshidrogenasa de tipo 1
UY29360A1 (es) Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones.
ECSP088306A (es) Agentes para prevenir y tratar los trastornos que involucran la modulación de los receptores ryr
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
UY28215A1 (es) Quinazolinas utiles como moduladores de canales iónicos
ECSP088854A (es) Moduladores bencimidazolicos de vr1
DOP2011000076A (es) Derivados de heteroaril amidas y su uso como activadores de glucoquinasa
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
ECSP055912A (es) Compuestos de 2-aminocarbonil-quinolina como antagonistas del receptor de difosfato de adenosina en plaquetas
AR057222A1 (es) Agonistas del receptor del neuropeprtido -2
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
UY29003A1 (es) Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160518